186 related articles for article (PubMed ID: 16634536)
41. An update on the use of antifungal agents.
Martinez R
J Bras Pneumol; 2006; 32(5):449-60. PubMed ID: 17268750
[TBL] [Abstract][Full Text] [Related]
42. Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin.
Durand ML; Kim IK; D'Amico DJ; Loewenstein JI; Tobin EH; Kieval SJ; Martin SS; Azar DT; Miller FS; Lujan BJ; Miller JW
Am J Ophthalmol; 2005 Sep; 140(3):552-4. PubMed ID: 16139017
[TBL] [Abstract][Full Text] [Related]
43. Fungal infections in bone marrow transplant recipients.
Raman T; Marik PE
Expert Opin Pharmacother; 2006 Feb; 7(3):307-15. PubMed ID: 16448325
[TBL] [Abstract][Full Text] [Related]
44. Combination therapy for invasive aspergillosis.
Viscoli C
Clin Infect Dis; 2004 Sep; 39(6):803-5. PubMed ID: 15472811
[No Abstract] [Full Text] [Related]
45. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin.
Santos RP; Sánchez PJ; Mejias A; Benjamin DK; Walsh TJ; Patel S; Jafri HS
Pediatr Infect Dis J; 2007 Apr; 26(4):364-6. PubMed ID: 17414408
[TBL] [Abstract][Full Text] [Related]
46. Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.
Lewis RE; Albert ND; Kontoyiannis DP
Antimicrob Agents Chemother; 2014 Nov; 58(11):6767-72. PubMed ID: 25182639
[TBL] [Abstract][Full Text] [Related]
47. [symbol: see text]Caspofungin and [symbol: see text]voriconazole for fungal infections.
Drug Ther Bull; 2004 Jan; 42(1):5-8. PubMed ID: 14768298
[TBL] [Abstract][Full Text] [Related]
48. Voriconazole in the treatment of invasive aspergillosis in kidney transplant recipients.
Veroux M; Corona D; Gagliano M; Sorbello M; Macarone M; Cutuli M; Giuffrida G; Morello G; Paratore A; Veroux P
Transplant Proc; 2007; 39(6):1838-40. PubMed ID: 17692627
[TBL] [Abstract][Full Text] [Related]
49. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide.
Steinbach WJ; Schell WA; Miller JL; Perfect JR
J Clin Microbiol; 2003 Aug; 41(8):3981-5. PubMed ID: 12904435
[TBL] [Abstract][Full Text] [Related]
50. Retinal function assessed by ERG before and after induction of ocular aspergillosis and treatment by the anti-fungal, micafungin, in rabbits.
Harrison JM; Glickman RD; Ballentine CS; Trigo Y; Pena MA; Kurian P; Najvar LK; Kumar N; Patel AH; Sponsel WE; Graybill JR; Lloyd WC; Miller MM; Paris G; Trujillo F; Miller A; Melendez R
Doc Ophthalmol; 2005 Jan; 110(1):37-55. PubMed ID: 16249956
[TBL] [Abstract][Full Text] [Related]
51. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis.
Reed C; Ibrahim A; Edwards JE; Walot I; Spellberg B
Antimicrob Agents Chemother; 2006 Nov; 50(11):3968-9. PubMed ID: 17000743
[No Abstract] [Full Text] [Related]
52. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience.
Lass-Flörl C; Griff K; Mayr A; Petzer A; Gastl G; Bonatti H; Freund M; Kropshofer G; Dierich MP; Nachbaur D
Br J Haematol; 2005 Oct; 131(2):201-7. PubMed ID: 16197450
[TBL] [Abstract][Full Text] [Related]
53. CNS-aspergillosis: are there new treatment options?
Schwartz S; Thiel E
Mycoses; 2003; 46 Suppl 2():8-14. PubMed ID: 15055138
[TBL] [Abstract][Full Text] [Related]
54. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain.
Domínguez-Gil A; Martín I; García Vargas M; Del Castillo A; Díaz S; Sánchez C
Clin Drug Investig; 2007; 27(3):197-205. PubMed ID: 17305414
[TBL] [Abstract][Full Text] [Related]
55. [Fulminant invasive fungal sinusitis in immunosuppressed hosts -- pathognomic presentation in MRI].
Hahn U; Lengerke A; Küker W
Rofo; 2004 May; 176(5):758-60. PubMed ID: 15122477
[No Abstract] [Full Text] [Related]
56. Treatment of rhinocerebral mucormycosis by combination of endoscopic sinus debridement and amphotericin B.
Alobid I; Bernal M; Calvo C; Vilaseca I; Berenguer J; Alós L
Am J Rhinol; 2001; 15(5):327-31. PubMed ID: 11732820
[TBL] [Abstract][Full Text] [Related]
57. Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins.
Ibrahim AS; Gebremariam T; Luo G; Fu Y; French SW; Edwards JE; Spellberg B
Antimicrob Agents Chemother; 2011 Apr; 55(4):1768-70. PubMed ID: 21263057
[TBL] [Abstract][Full Text] [Related]
58. Combined antifungal treatment of visceral mucormycosis with caspofungin and liposomal amphotericin B.
Voitl P; Scheibenpflug C; Weber T; Janata O; Rokitansky AM
Eur J Clin Microbiol Infect Dis; 2002 Aug; 21(8):632-4. PubMed ID: 12226700
[No Abstract] [Full Text] [Related]
59. Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection.
Cacciapuoti A; Halpern J; Mendrick C; Norris C; Patel R; Loebenberg D
Antimicrob Agents Chemother; 2006 Jul; 50(7):2587-90. PubMed ID: 16801452
[TBL] [Abstract][Full Text] [Related]
60. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis.
Pavie J; Lacroix C; Hermoso DG; Robin M; Ferry C; Bergeron A; Feuilhade M; Dromer F; Gluckman E; Molina JM; Ribaud P
J Clin Microbiol; 2005 Sep; 43(9):4902-4. PubMed ID: 16145172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
